liraglutide

Pre-clinicalCompleted
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes

Conditions

Diabetes, Diabetes Mellitus, Type 2

Trial Timeline

Feb 1, 2011 → Mar 1, 2013

About liraglutide

liraglutide is a pre-clinical stage product being developed by Novo Nordisk for Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT01288326. Target conditions include Diabetes, Diabetes Mellitus, Type 2.

What happened to similar drugs?

20 of 20 similar drugs in Diabetes were approved

Approved (20) Terminated (0) Active (0)

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT06283641Pre-clinicalCompleted
NCT05438186Pre-clinicalWithdrawn
NCT03888157Pre-clinicalCompleted
NCT03560336Pre-clinicalCompleted
NCT03479762Pre-clinicalCompleted
NCT02967757Pre-clinicalCompleted
NCT02505334Phase 3Completed
NCT02472717Phase 2Withdrawn
NCT02255266Pre-clinicalCompleted
NCT02321878Pre-clinicalCompleted
NCT02207348Phase 1Completed
NCT01821846Pre-clinicalCompleted
NCT01890993Pre-clinicalCompleted
NCT01499108ApprovedCompleted
NCT01542242ApprovedTerminated
NCT01345734Pre-clinicalCompleted
NCT01394341ApprovedCompleted
NCT01403025Pre-clinicalCompleted
NCT01288326Pre-clinicalCompleted
NCT01212133Pre-clinicalCompleted